Beijing Wellcome Pharmaceuticals

===
Research conducted in Europe, the United States and other countries has confirmed that a new targeted drug called Tarceva has significant effects in the treatment of non-small cell lung cancer.
< Professor Romain Perez-Soler, director of the Oncology Department at Albert Einstein College of Medicine in the United States, recently said in an interview with Xinhua News Agency: Clinical trials have shown that this new drug is effective for all non-small cell lung cancer patients, especially for those with non-small cell lung cancer. Non-smokers and Asian patients. Tarceva can prolong the median survival time of patients and reduce the risk of death by %.
Tarceva Price< Tarceva is currently the only targeted drug in the world that has been proven to improve the survival of patients with non-small cell lung cancer. According to Perez-Soler, Tarceva is the only targeted drug on the U.S. market approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer.
< The expert also said that because Tarceva only acts on cancer cells, it will not cause chemotherapy-related side effects such as nausea, vomiting and hair loss. After receiving treatment with this drug, the patient's condition becomes stable and symptoms such as cough, dyspnea and pain related to lung cancer can be controlled and the patient's quality of life can be improved. In addition, taking Tarceva by mouth once a day is more convenient for patients and does not require them to go to the hospital for intravenous treatment.
< Statistics from the World Health Organization show that lung cancer is the number one cancer killer in the world. People die from lung cancer every second in the world. Non-small cell lung cancer accounts for more than % of the total number of lung cancers.
Tarceva Price< Studies have confirmed that more than half (%) of all patients with advanced non-small cell lung cancer who have r-activating mutations treated with Tarceva after one year of treatment with Tarceva of patients had no disease progression compared with only .% of those receiving chemotherapy. In addition, the proportion of patients who received Tarceva who experienced tumor response was more than twice as high as that of patients who received chemotherapy (% vs. %). From this point of view, Tarceva is more effective than general chemotherapy drugs in treating non-small cell lung cancer and can better suppress tumors, improve symptoms, and prolong survival.
< The study results confirm that Tarceva can significantly improve patient prognosis and extend overall survival (. months versus. months) and improve response rate compared with placebo, while gefitinib can significantly improve overall survival compared with placebo. However, there was no statistical difference. The results of two studies confirmed that erlotinib can achieve clear clinical benefit due to its excellent pharmacokinetic advantages. Subgroup analysis of the Tarceva study showed that survival was prolonged for all patients in the treatment group (regardless of gender, histological type, performance status, previous chemotherapy regimen and efficacy). The latest results published in 2018 show that Tarceva can significantly improve the survival of male squamous cell carcinoma patients who smoke. The survival benefit of Tarceva was significant only in patients with high r/r+ and r/r gene copy numbers.